Exploring the impact of route of administration on medication acceptance in hospitalized patients: Implications for venous thromboembolism prevention

Popoola, Victor O.; Tavakoli, Farrah; Lau, Brandyn; Lankiewicz, Matthew; Ross, Patricia A.; Kraus, Peggy S.; Shaffer, Dauryne L.; Hobson, Deborah B.; Aboagye, Jonathan; Farrow, Norma E.; Haut, Elliott R.; Streiff, Michael B.

doi:10.1016/j.thromres.2017.10.012

Cited by 26 publications

(19 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If pharmacological prophylaxis is contraindicated, mechanical VTE prophylaxis (intermittent pneumatic compression) should be considered in immobilized patients (64,65). Missed doses of pharmacologic VTE prophylaxis are common and are likely associated with worse outcomes (66). Therefore, every effort should be made to ensure that patients receive all scheduled doses of pharmacologic VTE prophylaxis.…”

Section: Risk Stratification and In-hospital Prophylaxismentioning

confidence: 99%

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

Bikdeli

Madhavan

Jiménez

et al. 2020

Journal of the American College of Cardiology

2,751

3,005

View full text Add to dashboard Cite

Patients with acute respiratory distress syndrome due to infection with the novel coronavirus SARS-COV2 are currently considered at high risk of developing thromboembolic complications in both venous and arterial vessels. The use of anticoagulants for preventive or curative purposes should be considered to reduce the risk of thromboembolic events. We report a case of a patient with severe COVID-19 acute respiratory distress syndrome who consecutively developed a right femoral deep vein thrombosis related to the femoral central line and acute ischemia of the left upper limb related to a radial arterial line. He was under a therapeutic dose of low molecular weight heparin twice a day three days before. The femoral vein was free of thrombosis while the central line was placed under a duplex ultrasound. Thromboembolic events can occur in patients with severe COVID-19 despite therapeutic anticoagulants. Close monitoring of vascular access with duplex ultrasound may be required.

show abstract

Section: Risk Stratification and In-hospital Prophylaxismentioning

confidence: 99%

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

Bikdeli

Madhavan

Jiménez

et al. 2020

Journal of the American College of Cardiology

2,751

3,005

View full text Add to dashboard Cite

show abstract

“…10,11,25) In another study, 66.9% of patients who experienced DVT and/or PE events were diagnosed within the first month after hospital discharge, with 19.9% between months 1 and 2, and 13.2% between months 2 and 3. 26) In the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) registry of 15,156 patients, the median time for all VTE events was 17 days (interquartile range 6-43 days), and the median time for post-discharge VTE events was 44 days (interquartile range 25-68 days). 27) In an effort to increase compliance and safety in preventing VTEs post-hospitalization, multiple randomized control trials have been performed examining the utility and safety of several novel oral anticoagulants in the use of extended duration VTE prophylaxis.…”

Section: Extended Prophylaxis After Dischargementioning

confidence: 99%

Recommendations for VTE Prophylaxis in Medically Ill Patients

Skeik

Westergard

2020

Annals of Vascular Diseases

View full text Add to dashboard Cite

Venous thromboembolism (VTE) remains highly prevalent in medically ill patients, and often leads to increased mortality and cost burden during hospitalization and post-discharge. Nearly half of all VTEs occur during or after hospitalization, with pulmonary embolism accounting for 10% of inpatient mortality. Appropriate prophylaxis in high-risk medically ill patients has been shown to reduce risk of VTE and related mortality. Despite current evidence-based guidelines, VTE prophylaxis has been under-used. This owes greatly to ambiguity and concerns related to appropriate patient and prophylactic agent selection, and duration of prophylaxis. Because many acutely ill medical patients have multiple comorbidities, the risk of major bleeding must be considered when choosing to implement pharmacological VTE prophylaxis. Multiple risk assessment models have been developed and validated to help estimate VTE and bleeding risks in this population. While studies have shown that the risk for VTE often extends far beyond hospital discharge, there is no evidence to support extending prophylaxis after hospital discharge. The appropriate selection of VTE prophylaxis requires consideration for cost, availability, patient preference, compliance, and underlying comorbidities. Our paper reviews the current evidence and reasoning for appropriate selection of VTE prophylaxis in acutely medical ill patients, and highlights our own approach and recommendations.

show abstract

“…Additionally, use of an oral agent should reduce nonadherence often seen with subcutaneous VTE thromboprophylaxis regimens. 26 However, betrixaban has additional bleed risk without a FDA-approved antidote to reverse betrixaban-related bleeding. Currently, andexanet alfa is being studied as an antidote for other FXa inhibitors in the ongoing ANNEXA-4 trial, and its protocol may be amended to incorporate betrixaban users.…”

Section: Discussionmentioning

confidence: 99%

Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients

et al. 2018

View full text Add to dashboard Cite

show abstract

Exploring the impact of route of administration on medication acceptance in hospitalized patients: Implications for venous thromboembolism prevention

Cited by 26 publications

References 21 publications

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

Recommendations for VTE Prophylaxis in Medically Ill Patients

Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients

Contact Info

Product

Resources

About